Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial Journal Article

Local Library Link: Find It @ Loyola

Authors: Escudier, B.; Michaelson, M. D.; Motzer, R. J.; Hutson, T. E.; Clark, J. I.; Lim, H. Y.; Porfiri, E.; Zalewski, P.; Kannourakis, G.; Staehler, M.; Tarazi, J.; Rosbrook, B.; Cisar, L.; Hariharan, S.; Kim, S; Rini, B. I.
Article Title: Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
Abstract: BACKGROUND: In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines. METHODS: In post hoc analyses, patients were grouped by objective response to prior therapy (yes vs no), prior therapy duration ( vs median), and tumour burden (baseline sum of the longest diameter vs median). PFS and overall survival (OS), and safety by type and duration of prior therapy were evaluated. RESULTS: Response to prior therapy did not influence outcome with second-line axitinib or sorafenib. PFS was significantly longer in axitinib-treated patients who received longer prior cytokine treatment and sorafenib-treated patients with smaller tumour burden following sunitinib. Overall survival with the second-line therapy was longer in patients who received longer duration of prior therapy, although not significant in the sunitinib-to-axitinib sequence subgroup; OS was also longer in patients with smaller tumour burden, but not significant in the cytokine-to-axitinib sequence subgroup. Safety profiles differed modestly by type and duration of prior therapy. CONCLUSIONS: AXIS data suggest that longer duration of the first-line therapy generally yields better outcome with the second-line therapy and that lack of response to first-line therapy does not preclude positive clinical outcomes with a second-line vascular endothelial growth factor-targeted agent in patients with advanced RCC.
Journal Title: British journal of cancer
Volume: 110
Issue: 12
ISSN: 1532-1827; 0007-0920
Publisher: Unknown  
Journal Place: England
Date Published: 2014
Start Page: 2821
End Page: 2828
Language: eng
DOI/URL:

10.1038/bjc.2014.244
Notes: LR: 20141120; ClinicalTrials.gov/NCT00678392; JID: 0370635; 0 (Antineoplastic Agents); 0 (Cytokines); 0 (Imidazoles); 0 (Indazoles); 0 (Indoles); 0 (Phenylurea Compounds); 0 (Protein Kinase Inhibitors); 0 (Pyrroles); 0 (sunitinib); 25X51I8RD4 (Niacinamide); 9ZOQ3TZI87 (sorafenib); C9LVQ0YUXG (axitinib); OID: NLM: PMC4056058; 2014/02/10 [received]; 2014/04/07 [revised]; 2014/04/10 [accepted]; 2014/05/13 [aheadofprint]; ppublish